Specific changes in the mammalian gut microbiome as a biomarker for oxytocin-induced behavioral changes
Article (Published version)
Metadata
Show full item recordAbstract
Humans are colonized by bacteria, fungi, archaea, and viruses, which are collectively referred to as the microbiome. Most of the microbiome resides in the gut and may easily be investigated via stool sampling and subsequent metagenomic DNA sequencing. Prolonged exposure to psychiatric pharmacological agents is often associated with marked gastrointestinal phenomena, including changes in food intake, bowel motility, gastric emptying, and transit time [1–3]. Unlike the relatively objective measurement of the microbiota composition, accurate assessment of patients’ therapy adherence and treatment outcomes represent a challenge in psychiatric medical care [4]. This is partly because, for most psychopharmacological agents, compliance and response to treatments are subjectively assessed based on self-reporting and physicians’ evaluations [5,6]. An interesting alternative is having changes in the psychiatric patients’ gut microbiota composition serve as a measurable proxy for monitoring patie...nts’ compliance and the therapeutic effects of some drugs. It is yet unclear how behavioral changes and drug intake affect the microbiota; however, mounting evidence suggests that physical and mental disturbances may lead to changes in gastrointestinal (GI) motility [7,8] in both animals and humans [9–11]. Indeed, in humans, anger, fear, pain, and anxiety, as well as intensive exercise, results in changes in GI activity [8]. In rats, chronic stress results in initial delayed gastric emptying followed by acceleration later on [12]. Medication intake [13,14] and changes in stool consistency, gastric transit, and emptying time [15,16] also have a great impact on microbial composition.
Keywords:
Biomarker / Gut-brain axis / Microbiome / Oxytocin / PsychiatrySource:
Microorganisms, 2021, 9, 9Publisher:
- MDPI
Funding / projects:
DOI: 10.3390/microorganisms9091938
ISSN: 2076-2607
WoS: 000701179800001
Scopus: 2-s2.0-85114648124
Collections
Institution/Community
PharmacyTY - JOUR AU - Dangoor, Itzhak AU - Stanić, Dušanka AU - Reshef, Leah AU - Pešić, Vesna AU - Gophna, Uri PY - 2021 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3965 AB - Humans are colonized by bacteria, fungi, archaea, and viruses, which are collectively referred to as the microbiome. Most of the microbiome resides in the gut and may easily be investigated via stool sampling and subsequent metagenomic DNA sequencing. Prolonged exposure to psychiatric pharmacological agents is often associated with marked gastrointestinal phenomena, including changes in food intake, bowel motility, gastric emptying, and transit time [1–3]. Unlike the relatively objective measurement of the microbiota composition, accurate assessment of patients’ therapy adherence and treatment outcomes represent a challenge in psychiatric medical care [4]. This is partly because, for most psychopharmacological agents, compliance and response to treatments are subjectively assessed based on self-reporting and physicians’ evaluations [5,6]. An interesting alternative is having changes in the psychiatric patients’ gut microbiota composition serve as a measurable proxy for monitoring patients’ compliance and the therapeutic effects of some drugs. It is yet unclear how behavioral changes and drug intake affect the microbiota; however, mounting evidence suggests that physical and mental disturbances may lead to changes in gastrointestinal (GI) motility [7,8] in both animals and humans [9–11]. Indeed, in humans, anger, fear, pain, and anxiety, as well as intensive exercise, results in changes in GI activity [8]. In rats, chronic stress results in initial delayed gastric emptying followed by acceleration later on [12]. Medication intake [13,14] and changes in stool consistency, gastric transit, and emptying time [15,16] also have a great impact on microbial composition. PB - MDPI T2 - Microorganisms T1 - Specific changes in the mammalian gut microbiome as a biomarker for oxytocin-induced behavioral changes VL - 9 IS - 9 DO - 10.3390/microorganisms9091938 ER -
@article{ author = "Dangoor, Itzhak and Stanić, Dušanka and Reshef, Leah and Pešić, Vesna and Gophna, Uri", year = "2021", abstract = "Humans are colonized by bacteria, fungi, archaea, and viruses, which are collectively referred to as the microbiome. Most of the microbiome resides in the gut and may easily be investigated via stool sampling and subsequent metagenomic DNA sequencing. Prolonged exposure to psychiatric pharmacological agents is often associated with marked gastrointestinal phenomena, including changes in food intake, bowel motility, gastric emptying, and transit time [1–3]. Unlike the relatively objective measurement of the microbiota composition, accurate assessment of patients’ therapy adherence and treatment outcomes represent a challenge in psychiatric medical care [4]. This is partly because, for most psychopharmacological agents, compliance and response to treatments are subjectively assessed based on self-reporting and physicians’ evaluations [5,6]. An interesting alternative is having changes in the psychiatric patients’ gut microbiota composition serve as a measurable proxy for monitoring patients’ compliance and the therapeutic effects of some drugs. It is yet unclear how behavioral changes and drug intake affect the microbiota; however, mounting evidence suggests that physical and mental disturbances may lead to changes in gastrointestinal (GI) motility [7,8] in both animals and humans [9–11]. Indeed, in humans, anger, fear, pain, and anxiety, as well as intensive exercise, results in changes in GI activity [8]. In rats, chronic stress results in initial delayed gastric emptying followed by acceleration later on [12]. Medication intake [13,14] and changes in stool consistency, gastric transit, and emptying time [15,16] also have a great impact on microbial composition.", publisher = "MDPI", journal = "Microorganisms", title = "Specific changes in the mammalian gut microbiome as a biomarker for oxytocin-induced behavioral changes", volume = "9", number = "9", doi = "10.3390/microorganisms9091938" }
Dangoor, I., Stanić, D., Reshef, L., Pešić, V.,& Gophna, U.. (2021). Specific changes in the mammalian gut microbiome as a biomarker for oxytocin-induced behavioral changes. in Microorganisms MDPI., 9(9). https://doi.org/10.3390/microorganisms9091938
Dangoor I, Stanić D, Reshef L, Pešić V, Gophna U. Specific changes in the mammalian gut microbiome as a biomarker for oxytocin-induced behavioral changes. in Microorganisms. 2021;9(9). doi:10.3390/microorganisms9091938 .
Dangoor, Itzhak, Stanić, Dušanka, Reshef, Leah, Pešić, Vesna, Gophna, Uri, "Specific changes in the mammalian gut microbiome as a biomarker for oxytocin-induced behavioral changes" in Microorganisms, 9, no. 9 (2021), https://doi.org/10.3390/microorganisms9091938 . .